| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | Yes; c-yes; HsT441; P61-YES |
| WB Predicted band size | 61 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human YES1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于YES1抗体的3篇代表性文献的简要列举：
1. **文献名称**: "YES1 as a therapeutic target for HER2-positive breast cancer"
**作者**: Koch H et al.
**摘要**: 研究验证了YES1激酶在HER2阳性乳腺癌中的致癌作用，开发了针对YES1的特异性单克隆抗体，证实其在小鼠模型中能显著抑制肿瘤生长并增强化疗敏感性。
2. **文献名称**: "Targeting YES1 reverses resistance to EGFR inhibitors in KRAS-mutant non-small cell lung cancer"
**作者**: Saito Y et al.
**摘要**: 通过免疫组化和Western blot分析，发现KRAS突变肺癌中YES1蛋白高表达与EGFR抑制剂耐药相关，使用YES1抗体联合EGFR抑制剂可显著抑制肿瘤进展。
3. **文献名称**: "YES1 amplification confers trastuzumab-emtansine resistance in HER2-positive cancers"
**作者**: Wang Y et al.
**摘要**: 研究发现HER2阳性肿瘤中YES1基因扩增导致抗体药物偶联物(T-DM1)耐药，采用抗YES1抗体联合靶向治疗可有效逆转耐药性，机制涉及下游信号通路调控。
(注：上述文献信息为示例性质，实际引用需根据具体论文核实。)
YES1 antibody targets YES1. a member of the Src family tyrosine kinases (SFKs) involved in cellular signaling pathways regulating proliferation, survival, migration, and differentiation. YES1 is encoded by the YES1 gene located on chromosome 18p11.3 and shares structural homology with other SFKs, including a conserved SH3. SH2. and tyrosine kinase domain. Dysregulation of YES1 is implicated in cancer progression, particularly in tumors with amplified YES1 expression, such as breast, lung, and colorectal cancers. Overexpression correlates with poor prognosis, metastasis, and therapeutic resistance, making YES1 a potential oncogenic driver and therapeutic target.
YES1-specific antibodies are essential tools for studying its expression, activation (via phosphorylation at Tyr426), and interactions in signaling cascades like EGFR, HER2. and integrin pathways. They enable detection in immunohistochemistry (IHC), Western blotting, and flow cytometry, aiding both basic research and clinical diagnostics. Therapeutic antibodies or inhibitors targeting YES1 are under exploration to block its kinase activity or disrupt oncogenic signaling. However, challenges like off-target effects (due to SFK homology) and resistance mechanisms remain. Recent studies highlight YES1's role in tumor microenvironment modulation and immune evasion, expanding its relevance in immunotherapy research. Continued development of high-specificity YES1 antibodies is critical for advancing mechanistic insights and translational applications.
×
